181 related articles for article (PubMed ID: 28730569)
1. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
3. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Cunha LL; Marcello MA; Nonogaki S; Morari EC; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2015 Aug; 83(2):246-53. PubMed ID: 25130519
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis.
Cho JG; Byeon HK; Oh KH; Baek SK; Kwon SY; Jung KY; Woo JS
Eur Arch Otorhinolaryngol; 2018 Sep; 275(9):2355-2361. PubMed ID: 30019191
[TBL] [Abstract][Full Text] [Related]
5. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment.
Sulaieva O; Chernenko O; Selesnov O; Nechay O; Maievskyi O; Falalyeyeva T; Kobyliak N; Tsyryuk O; Penchuk Y; Shapochka D
Endocrinol Metab (Seoul); 2020 Jun; 35(2):443-455. PubMed ID: 32615729
[TBL] [Abstract][Full Text] [Related]
7. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.
Lu H; Zhang L; Dai Y; Ruan Y; Cao X; Cai X; Ruan S; Chen Q
Diagn Pathol; 2020 Feb; 15(1):16. PubMed ID: 32050977
[TBL] [Abstract][Full Text] [Related]
8. Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.
Liu X; Liu H; Wang L; Han Y; Kong L; Zhang X
Diagn Pathol; 2024 Feb; 19(1):29. PubMed ID: 38341587
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma.
Jeon MJ; Yoon JH; Han JM; Yim JH; Hong SJ; Song DE; Ryu JS; Kim TY; Shong YK; Kim WB
Eur J Endocrinol; 2013 Feb; 168(2):219-25. PubMed ID: 23161752
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma.
Wei T; Chen R; Zou X; Liu F; Li Z; Zhu J
Eur J Surg Oncol; 2015 Jun; 41(6):746-50. PubMed ID: 25882035
[TBL] [Abstract][Full Text] [Related]
11. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.
French JD; Weber ZJ; Fretwell DL; Said S; Klopper JP; Haugen BR
J Clin Endocrinol Metab; 2010 May; 95(5):2325-33. PubMed ID: 20207826
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary study of patterns of level IIb lymph node metastasis in papillary thyroid carcinoma].
Wan H; Zhang B; Liu S; Li Z; Wu Y; Wang X; Xu Z; Tang P
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 49(1):27-30. PubMed ID: 24680333
[TBL] [Abstract][Full Text] [Related]
14. Cervical Lymph Node Metastases After Thyroidectomy for Papillary Thyroid Carcinoma Usually Remain Stable for Years.
Tomoda C; Sugino K; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2016 Dec; 26(12):1706-1711. PubMed ID: 27616725
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.
Randolph GW; Duh QY; Heller KS; LiVolsi VA; Mandel SJ; Steward DL; Tufano RP; Tuttle RM;
Thyroid; 2012 Nov; 22(11):1144-52. PubMed ID: 23083442
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract][Full Text] [Related]
17. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
18. Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration.
Ozaki O; Ito K; Mimura T; Sugino K; Hosoda Y
Am J Surg Pathol; 1996 Jun; 20(6):695-8. PubMed ID: 8651348
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract][Full Text] [Related]
20. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
